sctv01c
Vaccineexperimental
Clinical trial activity
16 trials · 2 clinical orgs · 0 marketing orgs
Phase 1
3
Phase 2
16
Phase 3
3
Phase 4
0
Earliest trial started Dec 1, 2021 (NCT05148091)
Timeline
Indications
Studied for
Mechanism of action
- SARS-CoV-2Immunity, active
SARS-CoV-2 immunity, active
Chemistry & pharmacology
Oral
No
Parenteral
No
Topical
No
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT05933512 | Phase 2 | Aug 10, 2023 | Sinocelltech Ltd. |
| NCT05308576 | Phase 3 | Mar 31, 2023 | Sinocelltech Ltd. |
| NCT05683561 | Phase 3 | Jan 25, 2023 | Sinocelltech Ltd. |
| NCT05652543 | Phase 2 | Dec 31, 2022 | Sinocelltech Ltd. |
| NCT05522829 | Phase 2 | Oct 15, 2022 | Sinocelltech Ltd. |
| NCT05345873 | Phase 2 | Jul 1, 2022 | Sinocelltech Ltd. |
| NCT05329051 | Phase 2 | Jul 1, 2022 | Sinocelltech Ltd. |
| NCT05323461 | Phase 3 | May 10, 2022 | Sinocelltech Ltd. |
| NCT05239806 | Phase 2 | Apr 1, 2022 | Sinocelltech Ltd. |
| NCT05308602 | Phase 2 | Apr 1, 2022 | Sinocelltech Ltd. |
| NCT05238441 | Phase 2 | Mar 20, 2022 | Sinocelltech Ltd. |
| NCT05238454 | Phase 2 | Mar 20, 2022 | Sinocelltech Ltd. |
| NCT05239975 | Phase 2 | Feb 25, 2022 | Sinocelltech Ltd. |
| NCT05043311 | Phase 1/Phase 2 (Phase 2) | Jan 1, 2022 | Sinocelltech Ltd. |
| NCT05043285 | Phase 1/Phase 2 (Phase 2) | Jan 1, 2022 | Sinocelltech Ltd. |
| NCT05148091 | Phase 1/Phase 2 (Phase 2) | Dec 1, 2021 | Peking University, Sinocelltech Ltd. |
Showing 16 of 16 trials
Page 1 / 1
Organizations
Research & Development (2)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| Sinocelltech Ltd. | For profit | 16 | 16 | 2 | 2021 |
| Peking University | Academic/Hospital | 1 | 0 | 1 | 2021 |
2 organizations
Page 1 / 1